DPYD testing identifies inherited variants that can make fluorouracil or capecitabine dangerously difficult to clear. Results help clinicians choose treatment and starting doses, but a negative genetic screen does not guarantee safety.
- DPYD testing checks inherited DNA variants associated with reduced breakdown of fluorouracil and capecitabine; it does not directly measure enzyme activity.
- DPD deficiency can increase the risk of severe diarrhea, mouth damage, low neutrophils, neurological toxicity, and potentially fatal reactions.
- Activity score 2 usually indicates a predicted normal metabolizer for the variants assessed, not zero chemotherapy toxicity risk.
- Activity scores 1 and 1.5 generally lead to a clinician-selected reduced starting dose; CPIC's updated recommendation commonly starts at approximately 50% of the standard fluoropyrimidine dose.
- Activity scores 0 and 0.5 indicate predicted poor metabolism, for which fluoropyrimidines are generally avoided or considered only under exceptional specialist supervision.
- Uracil testing is an indirect DPD assessment; some European protocols use 16 ng/mL and 150 ng/mL decision thresholds, but these are not universal reference limits.
- Negative DPYD test results mean no reportable variant was found within that assay's coverage; rare variants, incomplete coverage, and other toxicity mechanisms remain possible.
- 緊急性のある症状 require immediate oncology advice even after a negative result; a temperature of 38.0°C or higher during chemotherapy is a common urgent contact threshold.
- 投与量決定 belong to the oncology team. Patients should not calculate, reduce, restart, or increase chemotherapy doses from an activity score themselves.
What does DPYD testing tell you before chemotherapy?
DPYD testing identifies inherited gene variants that can reduce clearance of fluorouracil and capecitabine, increasing the risk of severe or fatal toxicity. Clinicians use the result to select treatment and starting doses; a negative genetic result does not exclude DPD deficiency or other causes of toxicity.
DPYD is the gene; DPD is the enzyme it encodes. The distinction matters because a report describing 4 tested variants answers a narrower question than a report assessing enzyme function: it tells the oncologist whether those particular inherited changes were detected, not how efficiently every pathway will handle chemotherapy.
A positive DPYD result is a drug-safety finding, not a cancer diagnosis or a prediction that treatment will fail. Consider a hypothetical 58-year-old preparing for capecitabine: identifying one reduced-function allele before cycle 1 may allow the team to plan a safer start rather than discover impaired clearance after severe symptoms develop.
Kantesti is an AI blood test interpretation platform that helps explain laboratory terminology, while chemotherapy prescribing remains with the oncology team. As of October 7, 2026, this article separates established recommendations from laboratory-specific practice; our 組織と臨床目的 explain where educational interpretation fits, rather than presenting an AI explanation as a second prescription.
Why do DPYD gene variants increase fluoropyrimidine toxicity?
Reduced-function DPYD gene variants can decrease DPD activity, allowing fluorouracil exposure to rise at an otherwise standard dose. Capecitabine is converted into fluorouracil inside the body, so taking chemotherapy as tablets does not bypass this metabolic risk.
DPD normally breaks down approximately 80% of administered fluorouracil through its principal catabolic pathway. When that first breakdown step is impaired, a dose chosen using body surface area can produce greater and more prolonged exposure than intended; the resulting toxicity is not simply an allergy to the drug.
Fluorouracil affects rapidly renewing intestinal lining and marrow cells as part of its pharmacology. Excess exposure therefore helps explain the combination of severe diarrhea, extensive mouth soreness, and falling neutrophils during cycle 1, although neurological and cardiac complications can also occur without that complete pattern.
Pharmacogenetic tests are specific to the drug pathway they assess. A normal DPYD result does not establish safe handling of azathioprine, just as a normal アザチオプリン投与前の TPMT 結果 does not establish fluorouracil safety; these are separate enzymes, separate genes, and separate prescribing decisions.
How is genetic testing different from a DPD deficiency test?
DPYD genetic testing examines DNA, whereas DPD assessment evaluates enzyme function directly or indirectly. The phrase “DPD deficiency test” can describe either approach, so patients should ask which method was actually performed rather than assuming the names are interchangeable.
A genotype result is usually stable throughout life, while a biochemical phenotype can vary with sampling conditions and physiology. A validated genetic assay may use a laboratory sample or a saliva specimen; an indirect phenotype commonly measures plasma uracil, and a specialized direct assay may measure DPD activity in peripheral mononuclear cells.
Plasma uracil is an indirect marker because DPD also breaks down naturally occurring uracil. A value reported in ng/mL therefore reflects both enzyme-related handling and potential confounders; it is not equivalent to measuring the percentage of chemotherapy that an individual will safely metabolize.
Neither method automatically replaces the other when clinical suspicion remains high. A report saying “not detected” is a categorical result, while a uracil concentration is numerical; our explanation of 定性および定量結果 helps distinguish these formats without treating either one as a complete safety certificate.
Which DPYD gene variants are commonly included?
Many targeted DPYD panels assess four established risk variants: c.1905+1G>A, c.1679T>G, c.2846A>T, and a HapB3-associated variant. Broader panels and sequencing can assess additional changes, but the assay's actual coverage must be read from the laboratory report.
DPYD2A refers to c.1905+1G>A, and DPYD13 refers to c.1679T>G. These are generally classified as no-function alleles, whereas c.2846A>T and HapB3 are typically reduced-function findings; older star-allele names and nucleotide descriptions can therefore identify the same clinically relevant result.
HapB3 testing deserves a closer look because c.1236G>A may be used as a marker for the functional intronic variant c.1129-5923C>G. Marker relationships are not equally reliable in every population, so the laboratory should explain whether it measured the functional change, a validated proxy, or a haplotype inferred from several positions.
A four-variant panel does not capture all clinically relevant variation across ancestries. For example, c.557A>G, also described as p.Tyr186Cys, is relevant in some people with African ancestry and may be absent from a traditional European-focused panel; unlike many common MTHFR variant findings, established DPYD findings can directly change drug prescribing.
How do DPYD test results become an activity score?
A DPYD activity score combines the assigned function of both inherited alleles to predict fluoropyrimidine metabolism. In the commonly used CPIC framework, a normal-function allele scores 1, a reduced-function allele 0.5, and a no-function allele 0.
An activity score of 2 generally predicts normal metabolism, while scores of 1 or 1.5 predict intermediate metabolism. Scores of 0 or 0.5 predict poor metabolism; these categories support prescribing decisions but do not provide an exact measured percentage of DPD activity in an individual patient.
Two reported variants do not automatically mean that both copies of DPYD are affected. The changes may sit together on one chromosome, called cis, or on opposite chromosomes, called trans; resolving that phase can materially change interpretation, particularly when a report contains multiple rare variants rather than one familiar actionable finding.
A variant of uncertain significance is not a confirmed reduced-function allele. I, Thomas Klein, would separate the report into 3 questions: what was detected, what function the laboratory assigned, and what prescribing guidance applies; the same source-checking discipline appears in our medical report explanation safeguards.
Why does a negative DPYD result not eliminate risk?
A negative DPYD result excludes only reportable variants within that test's scope; it does not exclude every cause of reduced DPD activity or chemotherapy toxicity. Normal predicted metabolism also leaves risks from renal impairment, treatment combinations, dosing errors, and non-DPD mechanisms.
Severe toxicity remains possible after a negative four-variant screen. In Henricks and colleagues' prospective study of 1,103 evaluable patients, severe fluoropyrimidine-related toxicity occurred in 23% of non-carriers and 39% of identified variant carriers receiving genotype-guided treatment; these were treatment-context observations, not universal risk percentages for every regimen (Henricks et al., 2018).
The carrier and non-carrier figures should not be read as evidence that screening makes no difference. The study compared genotype-guided care with historical carrier risks rather than randomly assigning known high-risk patients to unchanged full doses; residual toxicity shows why monitoring remains necessary after cycle 1 begins.
Kantesti is an AI lab test interpretation service that treats a negative DPYD result as a bounded laboratory finding, not a guarantee of chemotherapy safety. Similar caution applies when interpreting low G6PD enzyme activity: a drug-safety assessment must match the method, the clinical setting, and the particular medicine.
What do plasma uracil results mean for DPD assessment?
Plasma uracil can support indirect assessment of DPD activity, but thresholds depend on the laboratory and clinical protocol. Some European pathways use less than 16 ng/mL, 16 to less than 150 ng/mL, and 150 ng/mL or higher as treatment-planning categories.
A uracil result of 16 ng/mL is not a biological cliff where risk suddenly begins. These operational thresholds help standardize decisions, but assay variation, kidney function, and collection conditions can change classification around the boundary; the oncology team should use the reporting laboratory's validated interpretation rather than a number copied from another country.
Uracil samples can be sensitive to delays before separation and to transport conditions. The exact time and temperature requirements belong to the performing laboratory, and a compromised specimen may need reassessment; our guide to sample-related laboratory errors explains why sample quality matters, although hemolysis and uracil handling are not the same problem.
Reduced kidney function can raise plasma uracil and complicate its use as a DPD marker. A result of 20 ng/mL during dehydration deserves different scrutiny from the same result under stable conditions; reviewing kidney estimates after dehydration can help patients understand why clinicians sometimes investigate a borderline phenotype before finalizing treatment.
What if genetic and DPD assessment results disagree?
Discordant DPYD genotype and DPD assessment results require reconciliation, not averaging. A negative genetic panel with elevated uracil can reflect incomplete variant coverage, biochemical confounding, or genuinely reduced function not explained by the tested variants.
A high-risk genetic finding should not be dismissed because one biochemical result appears reassuring. Genotype and phenotype measure different things, and a single uracil value below 16 ng/mL cannot automatically erase an established no-function allele; the oncology pharmacist or pharmacogenetics service should review the complete evidence.
An unexpectedly elevated uracil result should trigger a structured review of kidney function and specimen processing. Creatinine, estimated filtration, recent fluid losses, and the laboratory's handling record can help explain the discrepancy; our 腎機能解釈ガイド provides background, but a BUN-to-creatinine ratio does not diagnose DPD deficiency.
There is no validated rule that a reassuring genetic result and an abnormal phenotype cancel each other out. For a hypothetical patient with a four-variant negative panel and uracil of 24 ng/mL, reasonable specialist options may include confirming sample quality, repeating the phenotype under suitable conditions, extending genetic assessment, or selecting a cautious treatment strategy.
How do clinicians use DPYD results to choose doses?
Clinicians use DPYD results to select a starting strategy, then adjust treatment using tolerance, treatment intent, organ function, and sometimes fluorouracil exposure measurements. An activity score is not a patient-operated dosing calculator, and a reduced starting dose is not necessarily the final dose.
CPIC's updated guidance commonly recommends approximately a 50% starting-dose reduction for intermediate metabolizers with activity scores of 1 or 1.5. The original 2017 update was published in 2018, and its online recommendation was subsequently revised; clinicians should check the current linked guidance rather than relying on an older printed table (Amstutz et al., 2018).
Predicted poor metabolizers with activity scores of 0 or 0.5 are generally advised to avoid fluorouracil and capecitabine. If no suitable alternative exists, any exceptional fluoropyrimidine use requires specialist planning and very close monitoring; neither a standard tablet reduction nor an improvised percentage is an adequate substitute.
A fluoropyrimidine reduction does not automatically mean reducing every drug in a combination regimen. After cycle 1, the team may cautiously increase, maintain, or further reduce that component based on the patient's course; our 薬剤安全性トレンドガイド explains why symptoms and serial laboratory findings matter more than a one-time score alone.
Do international guidelines recommend the same testing approach?
International guidance agrees that DPD-related risk matters, but testing methods and implementation differ. The European Medicines Agency recommended pretreatment DPD assessment for systemic fluorouracil, capecitabine, and tegafur in 2020, using genotype and/or phenotype approaches according to local practice.
The EMA recommendation concerns systemic fluoropyrimidines, not every medicine containing a related chemical name. Its 2020 communication did not recommend routine pretreatment DPD testing for topical fluorouracil, whose systemic exposure is usually much lower; patients should still disclose known deficiency when any fluorouracil-containing treatment is considered (European Medicines Agency, 2020).
CPIC primarily explains how an available genotype should inform prescribing; it is not itself a universal screening mandate. European health systems have often built routine pretreatment pathways around this risk, while testing access and regulatory wording elsewhere vary; United States product labels and local oncology policies should be checked rather than inferred from a European algorithm.
Kantesti distinguishes general laboratory interpretation from evidence supporting a particular prescribing decision. Henricks et al. studied a defined four-variant strategy in 1,103 evaluable patients, not every possible sequencing panel or phenotype method; our 臨床方法論基準 should not be read as validation of automated chemotherapy selection.
What should patients ask before the test and first treatment?
Before treatment, ask which DPYD or DPD method is being used, when the result will return, and who will review it before the first dose. DNA testing usually does not require fasting, but phenotype collection instructions must come from the performing laboratory.
Turnaround time is a treatment-planning issue, not a fixed property of DPYD testing. A local assay may return in several days while a send-away test takes longer; before cycle 1, confirm whether the oncology team has received and acted on the result rather than assuming that sample collection means the safety assessment is complete.
A baseline complete blood count and kidney assessment answer questions that DPYD testing cannot. The team also needs the actual regimen, recent weight changes, previous fluoropyrimidine exposure, and current symptoms; our useful baseline testing checklist explains how to make a pretreatment laboratory panel interpretable.
The medication list should include prescriptions, non-prescription products, and recent antiviral treatment. Brivudine and related medicines can strongly inhibit DPD and cause dangerous interactions with fluoropyrimidines; the required separation interval is product-specific, often at least 4 weeks for brivudine, so an oncology pharmacist should verify it rather than patients applying a generic rule from our medication-effect review.
Which symptoms need urgent help despite a negative test?
Severe diarrhea, inability to drink, extensive mouth soreness, fever, confusion, or chest pain during fluorouracil or capecitabine treatment require urgent assessment. A negative DPYD test must never be used to dismiss symptoms, especially when they are unusually early or rapidly worsening.
A temperature of 38.0°C or higher during chemotherapy is a common urgent contact threshold, but the patient's oncology instructions take priority. Chest pain, new breathing difficulty, fainting, or confusion warrants emergency care; our chest pain assessment guide explains why waiting for a home interpretation or repeat genetic test is unsafe.
Chemotherapy-associated diarrhea can reflect toxicity, an infectious cause, or both. Four or more additional loose stools above the usual daily pattern, overnight diarrhea, dizziness, or reduced urine output should prompt same-day oncology contact, and severe symptoms need immediate assessment; our discussion of C. diff test interpretation explains one possible alternative cause without replacing urgent triage.
Uridine triacetate is a time-sensitive antidote used in appropriate cases of fluorouracil or capecitabine overdose or early severe toxicity. Its established treatment window is within 96 hours after the end of exposure, so emergency clinicians need the exact last tablet or infusion time; patients should follow their written toxicity plan and urgently obtain instructions about further doses rather than inventing a reduced schedule.
What monitoring is needed after chemotherapy starts?
Monitoring remains necessary after every DPYD result because genetic screening cannot predict all treatment toxicity. Clinicians combine symptoms with complete blood counts, renal function, electrolytes, and regimen-specific checks; selected infusional fluorouracil regimens may also use therapeutic drug monitoring.
The absolute neutrophil count is more useful than the neutrophil percentage alone when assessing treatment-related marrow suppression. An ANC below 0.5 × 10^9/L represents severe neutropenia and substantially increases infection concern, particularly with fever; our 絶対好中球数ガイド explains the units and why a normal baseline count does not guarantee a normal later count.
Diarrhea and poor intake can alter kidney function and electrolytes even when DPYD metabolism was predicted to be normal. This matters particularly for capecitabine because renal impairment can increase exposure to relevant metabolites; our electrolyte interpretation guide explains why potassium and sodium changes must be assessed alongside symptoms rather than blamed on genetics alone.
Kantesti is an AI biomarker interpretation platform that can help organize serial CBC, creatinine, and electrolyte results for clinical discussion. It does not measure fluorouracil exposure or determine cycle 2 dosing; specialized monitoring for some infusional fluorouracil regimens often uses an AUC target around 20–30 mg·h/L, but that target is not universal and is not a capecitabine tablet target.
How should you discuss DPYD results with your oncology team?
The most useful discussion turns the DPYD report into a documented treatment plan, not a self-directed dose change. Ask the team to explain assay coverage, the predicted metabolizer category, any phenotype result, the selected starting strategy, and the symptoms that require an urgent call.
For a positive result, ask whether the finding affects one or both inherited alleles and whether family discussion is appropriate. One carrier finding can matter for a relative's future fluoropyrimidine treatment, but relatives should not assume their own status or order broad testing without advice; record the actual variant rather than a vague note saying “chemotherapy allergy.”
At Kantesti, an educational explanation should preserve the distinction between prediction and measurement. 私たちの AI技術の説明 describes the interpretation workflow, while our 医療諮問委員会を identifies the physicians involved in clinical oversight; neither page establishes that an individual DPYD report has received a prescribing consultation or that this draft has undergone named human review.
My practical priority as Thomas Klein is a closed loop: result received, result interpreted, plan documented, emergency contact understood. If using Kantesti AI to explain a report, retain the original document and check variant spelling, units, and specimen details against it; our report upload privacy checklist addresses sensitive laboratory data, including genetic information, before optional upload.
よくある質問
化学療法前にDPYD検査を受けるのはなぜですか？
DPYD検査は、フルオロウラシルとカペシタビンの分解低下に関連する遺伝性DNA変異を調べます。多くのターゲットパネルは確立された4つのリスク変異を評価しますが、より広範なアッセイも利用可能です。結果は、腫瘍内科チームが治療法とより安全な開始用量を選択するのに役立ちます。遺伝子検査はDPD酵素活性を直接測定するものではなく、治療中のモニタリングに代わるものではありません。.
DPYD検査で陰性であれば、カペシタビンは安全ですか？
DPYD検査陰性であっても、カペシタビンが安全であること、または重度の毒性がないことを保証するものではありません。4つのバリアントパネルの陰性は、報告可能なバリアントが検出されなかったことを意味し、DPD欠乏のすべての関連するDPYDの変化または原因が除外されたことを意味するものではありません。腎機能障害、薬物相互作用、およびその他の治療関連メカニズムによってもリスクが増加する可能性があります。遺伝的結果に関係なく、重度の下痢、発熱、口内痛、錯乱、または胸痛は緊急の評価が必要です。.
DPYD活性値1.5とはどういう意味ですか？
1.5というDPYD活性スコアは、通常、正常機能アレルと機能低下アレルを1つずつ持つ予測中間代謝者を示します。CPICの更新された推奨事項は、このカテゴリーでは約50%のフルオロピリミジン開始用量を支持し、その後に臨床医主導の調整が行われることが一般的です。このスコアは、酵素活性が正常の正確に75%であることを直接示す測定値ではありません。患者は、このスコアから化学療法の用量を自分で計算したり変更したりしてはいけません。.
DPD欠損症検査はDPYD遺伝子検査と同じですか？
DPD欠損検査はDPYD遺伝子検査と必ずしも同じではありません。なぜなら、検査室では異なる方法を示すためにこの用語を使用しているからです。DPYD検査はDNAを調べますが、表現型評価では血漿ウラシルまたはDPD酵素の特殊活性を測定することがあります。一部のヨーロッパのウラシルプロトコルでは16 ng/mLおよび150 ng/mLの判断閾値が使用されていますが、これらは普遍的な参照限界ではありません。結果を解釈する前に、検査室の方法と現地の処方プロトコルを確認する必要があります。.
Can plasma uracil be high without an actionable DPYD variant?
Plasma uracil can be elevated even when a targeted DPYD panel finds no actionable variant. Kidney impairment, specimen processing problems, and genetic changes outside the panel's coverage can contribute to this pattern. A result such as 20 ng/mL therefore requires interpretation using the laboratory's method, clinical protocol, and the patient's condition. The oncology team may investigate confounders or seek additional assessment rather than treating the genetic and biochemical results as mutually cancelling.
Do I need to repeat DPYD testing before every chemotherapy cycle?
Inherited DPYD genotype is usually stable, so the same validated genetic test generally does not need repeating before every cycle. A repeat or expanded test may be useful if the original report is unavailable, assay coverage was limited, or the interpretation is uncertain. CBC, kidney function, electrolytes, and symptoms still need monitoring according to the regimen, including before cycle 2 when required. Biochemical DPD assessment may need reassessment if sample quality or physiological confounding is suspected.
What should I do if severe symptoms occur after fluorouracil or capecitabine?
Severe or rapidly worsening symptoms after fluorouracil or capecitabine require immediate oncology advice or emergency assessment, even after a negative DPYD result. A temperature of 38.0°C or higher is a common urgent contact threshold during chemotherapy, while chest pain, confusion, fainting, or breathing difficulty warrants emergency care. Clinicians may consider uridine triacetate for appropriate overdose or early severe toxicity cases within 96 hours after the end of exposure. Follow the written toxicity plan and obtain urgent instructions about further doses rather than creating a reduced schedule yourself.
今日、AIによる血液検査分析を
いますぐ利用しませんか。即時で正確な検査分析を提供するKantestiを信頼する、世界中の200万人以上のユーザーに参加してください。血液検査結果をアップロードすると、15,000+のバイオマーカーについて数秒で包括的な解釈が得られます。.
📚 参考文献
📖 外部の医学的参考文献
Amstutz U et al. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.。 Clinical Pharmacology & Therapeutics。.
Henricks LM et al. (2018). DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.。『The Lancet Oncology（ランセット・オンコロジー）』.
European Medicines Agency (2020). EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. European Medicines Agency safety communication.
⚕️ 医療免責事項
この記事は教育目的のみを対象としており、医療助言を構成するものではありません。診断や治療の判断を行う際は、必ず有資格の医療提供者にご相談ください。.
E-E-A-T 信頼性シグナル
経験
医師主導による、検査結果解釈ワークフローの臨床レビュー。.
専門知識
臨床的な文脈においてバイオマーカーがどのように振る舞うかに焦点を当てた検査医学。.
権威
トーマス・クライン博士が執筆し、サラ・ミッチェル博士およびハンス・ヴェーバー教授によるレビュー。.
信頼性
アラームを減らすための明確なフォローアップ経路を備えた、エビデンスに基づく解釈。.